Figure 12.
Kaplan–Meier plot of time from treatment to death. (A) Patients with LDH > 577 treated with rituxmab and doxorubicin had a significant prolongation of time from treatment to death, median not reached (95%CI 24.0–N/A, n = 14) months, as compared to nonrituximab nondoxorubicin regimens, median 4.9 (95%CI 2.0–N/A, n = 54) months (χ2 = 21.4, P < 0.0001). (B) The benefit of rituximab remained significant when the age effect was added into the analysis. In patients with age > 71 and LDH > 577, there was still a significant difference between rituximab and doxorubicin and nonrituximab nondoxorubicin treatments, median 20.0 (95%CI 14.0–N/A, n = 14) months versus 2.0 (95%CI 0.5–N/A, n = 5) months (χ2 = 4.7, P = 0.0304). LDH, lactate dehydrogenase.